REALVNC
9.6.2022 15:02:03 CEST | Business Wire | Press release
VNC Connect by RealVNC, the remote access service used by hundreds of millions of people worldwide, was audited by Cure53 , the Berlin, Germany-based IT security consultancy who have also audited other industry leading software such as Mozilla VPN, 1Password and Bitwarden. The comprehensive audit, which took 86 person days and included VNC Server and VNC Viewer on Linux, Windows and Mac, VNC Viewer for iOS and Android, the VNC Connect management portal and backend services, found 38 security-relevant discoveries, none of which were critical and only three were deemed high severity, and these were fixed immediately. The report states, in conclusion, that RealVNC places a strong focus on the security posture of all its components.
“As the technologists responsible for bringing remote access to the mass market, we are today setting new standards and expectations for security in the face of the challenges of the modern IT environment. IT buyers of remote access technologies should expect no less than independent and comprehensive third-party validation of vendor claims. This is especially true for remote access software where the stakes are high, and a mistake could be reputationally damaging or even existential. With Cure53’s report, buyers can be confident that choosing RealVNC as their remote access vendor will never be a regret,” said Adam Greenwood-Byrne, CEO of RealVNC.
A white box security audit is significantly more in-depth than the more common black box penetration test (which RealVNC also commissions by an external organization annually), as the auditors have access to all of the source code, binaries and API/protocol documentation. Of the 38 vulnerabilities found across the range of software and services tested, 32 have been properly addressed — with the fixes confirmed by Cure53 — while the other six were flagged as either false-alerts or works-as-intended and evaluated to be of lower risk.
“At RealVNC, we operate from the standpoint that no company should ever take a vendor’s word for it when they claim their software is secure, which is why we chose to complete a white box audit with a highly regarded security consultancy to prove it,” said Andrew Woodhouse, CIO of RealVNC.
The Cure53 team is highly motivated to find issues when completing white box penetration tests. The fact that no critical threats were found reinforces RealVNC’s focus on ensuring its customers remain safe from threats when using VNC Connect.
“Cure53 is happy to state that test preparation, test execution and also the fix verification, which is one of the most important parts of such an audit, went smoothly and professionally. It is clear that RealVNC has demonstrated a genuine interest in ensuring VNC Connect's security and is prepared and committed to maintaining the high standards we have observed,” said Dr.-Ing. Mario Heiderich, Founder of Cure53.
Headquartered in Cambridge, RealVNC's products for desktop, mobile and embedded platforms make it easy for users to access and operate devices remotely while enabling remote users to work with technicians to resolve problems easily.
“We’re not shying away from any of the issues the report found. We actively fixed issues as they came up and, as security is an ever changing landscape, we’ll continue to ensure the security of VNC Connect in future iterations of the service,” said Ben May, Head of Cyber Security at RealVNC.
To review Cure53's summary of the audit, click here , and to learn more about why RealVNC chose to conduct a Cure53 audit, click here .
ABOUT REALVNC
RealVNC’s secure remote access and management software is used by hundreds of millions of people worldwide. Their software helps organizations cut costs and improve the quality of supporting remote devices and applications, as well as enabling remote working. RealVNC is the original, UK-based, inventor of VNC remote access software and they support an unrivaled mix of desktop, mobile and embedded platforms.
ABOUT CURE53
Cure53 offers classic black-box penetration tests (zero-knowledge) as well as white-box tests and code audits. Web application and mobile app developers speak many languages and so do we. From classic languages such as PHP, JavaScript, ActionScript, Java, Ruby, Python and Perl to more exotic candidates like web back-ends written in C++ and Delphi – we've seen them.
Since Cure53 was founded in 2007, we have performed hundreds of penetration tests against all kinds of web applications, online services, hardware interfaces, mobile applications, libraries and crypto tools. We value manual and thorough tests, human interaction and communication and a short yet-to-the-point penetration test report without overhead or pie charts no one wants to see.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
